Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02783573 · ClinicalTrials.gov registry record · Phase 3
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Phase 3 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,722
- Enrollment target
NCT02783573: Clinical Trial Phase 3 study, sponsored by AstraZeneca.
NCT02783573 is a Phase 3 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 1,722 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (123% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02783573, a Phase 3 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,722 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the efficacy of the study drug known as lanabecestat in participants with mild Alzheimer's disease (AD) dementia.
Primary Outcome
ADAS-Cog13 (13-item version of ADAS Cog) is a psychometric instrument that evaluates word recall, ability to follow commands, constructional praxis, naming, ideational praxis, orientation, word recognition, memory, comprehension of spoken language, word-finding, and language ability, with a measure of delayed word recall and concentration/ distractibility. The total score of the 13-item scale ranges from 0 to 85, with an increase in score indicating cognitive worsening. Least Squares (LS) mean w
Interventions
- DRUG Placebo
- DRUG Lanabecestat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,722 participants |
| Start Date | 2016-07-01 |
| Est. Completion | 2018-09-28 |
| Phase | Phase 3 |
Why NCT02783573 stopped before completion
NCT02783573 is an interventional study that assigns participants to a tested intervention. Its 1,722 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (123% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02783573 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02783573 about?
NCT02783573 is a clinical study titled "A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia". The main purpose of this study is to evaluate the efficacy of the study drug known as lanabecestat in participants with mild Alzheimer's disease (AD) dementia.
What is the current status of trial NCT02783573?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,722 participants. The study started on 2016-07-01. Estimated completion is 2018-09-28.
What interventions are being tested in trial NCT02783573?
The interventions under investigation include: Placebo (DRUG), Lanabecestat (DRUG).
Who is sponsoring clinical trial NCT02783573?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02783573's enrollment target sits among peer trials
1,722 130th of 2000 higher than 1,871 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06898034 · 1,725 participants
Postpartum Ultrasound Evaluation to Assess Risk of Hemorrhage
- NCT04291612 · 1,715 participants
Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease
- NCT06413420 · 1,731 participants
SUNOSI® (Solriamfetol) Pregnancy Registry
- NCT05303636 · 1,710 participants · Phase 4
LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI